Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ProMetic Life Sciences -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (98)	5/11/2017 1:13:54 AM
From: axial	Respond to of 250

This was a deal based on Prometic's ability to extract IAIPs from plasma. It didn't cause much excitement, and there haven't been many signs of progress. " The agreements provide ProMetic with global, exclusive intellectual property rights to commercialize products for two clinical indications and both companies have strategic interest in the other’s IAIP-related therapeutic areas through a royalty- bearing cross-license agreement. Under the terms of the deal, ProMetic and ProThera each will perform development services in order to advance IAIP to the clinic by 2017. ProMetic has received an initial 11.25 % equity stake in ProThera and such equity position to be increased to 22.5% following the achievement of an early-stage development milestone. Further, ProMetic will exclusively manufacture IAIP for clinical trial requirements and commercial sales for all indications." ____________________________________ Another iron in Prometic's fire, but not hot yet. Good research. Thanks. Jim

To: scaram(o)uche who wrote (98)	9/25/2017 5:51:17 PM
From: axial	Respond to of 250

Corporate Presentation September 2017 * Note to readers * — For newer readers, on this thread I embed links like so — instead of this — prometic.com — So if you see a bolded and coloured item, just click on it. It will take you there instantly. No fuss, no muss. — Messages indicate some readers are missing this. They're not clicking on the links -- only reading the text -- unaware there's more information in the post. ________________________________________________ — Even for those knowledgeable about Prometic, the array of information is staggering. Products, potential products, timelines, financials, trials, global partnerships and more. It changes often, and the rate of change is expected to accelerate in coming years. — That is the reason for frequent updates, including analyst reports and corporate presentations. The purpose is continuous updating -- not promotion. Jim